News

Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

01/05/2024

Allison Casey

A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.

A real world study found triplet...

01/05/2024

Oncology

News

Darolutamide Benefit May Have Been Underestimated Among Patients With Non-Metastatic Castration-Resistant Prostate Cancer

12/12/2023

Allison Casey

According to sensitivity analyses, the original analysis of the ARAMIS trial may have underestimated the overall survival benefit of darolutamide among patients with non-metastatic castration-resistant prostate cancer.

According to sensitivity...

12/12/2023

Oncology

News

Olaparib Benefit for Patients With Metastatic Castration-Resistant Prostate and BRCA Alterations Consistent Across Subgroups

12/01/2023

Allison Casey

According to an exploratory subgroup analysis from the phase 3 PROfound trial, the rPFS and OS benefit from olaparib for patients with BRCA-altered metastatic castration-resistant prostate cancer was consistent across all subgroups.

According to an exploratory...

12/01/2023

Oncology

News

255AC-J591 Shows Preliminary Efficacy, Safety Among Patients with Metastatic Castration-Resistant Prostate Cancer

11/30/2023

Allison Casey

According to a phase 1 trial, a single dose of 255AC-J591 was safe and showed preliminary efficacy among patients with metastatic castration-resistant prostate cancer.

According to a phase 1 trial, a...

11/30/2023

Oncology

News

Enzalutamide Approved for Non-Metastatic Castration Sensitive Prostate Cancer With Biochemical Recurrence

11/21/2023

Allison Casey

On November 17, 2023, the FDA approved enzalutamide for patients with non-metastatic castration sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

On November 17, 2023, the FDA...

11/21/2023

Oncology

News

Adjuvant Radiotherapy Provided No Benefit Among Patients With Prostate Cancer Post-Radical Prostatectomy

11/10/2023

Allison Casey

Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.

Results from the phase 3...

11/10/2023

Oncology

News

Adjuvant Radiotherapy Provided No Benefit Among Patients With Prostate Cancer Post-Radical Prostatectomy

11/10/2023

Allison Casey

Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.

Results from the phase 3...

11/10/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone for BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Allison Casey

Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Niraparib plus abiraterone...

11/10/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone for BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Allison Casey

Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Niraparib plus abiraterone...

11/10/2023

Oncology

News

Addition of 177Lu-PSMA-617 to Enzalutamide Improves PSA Outcomes Among Patients With Metastatic Castration-Resistant Prostate Cancer

11/06/2023

Allison Casey

A phase 2 study found that adding adaptive-dosed 177Lu-PSMA-617to enzalutamide improved several PSA-based outcomes among patients with metastatic castration-resistant prostate cancer.

A phase 2 study found that...

11/06/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology